[Skip to Navigation]
January 27, 2021

Treatment of Grover Disease With Dupilumab

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco
  • 2Augusta University/University of Georgia Medical Partnership, Athens
JAMA Dermatol. 2021;157(3):353-356. doi:10.1001/jamadermatol.2020.5097

Grover disease is a benign but at times severely pruritic and treatment-refractory inflammatory disease that primarily affects older adults. The pathophysiology is poorly understood. It has been associated with medications, including chemotherapeutics, but most commonly occurs without a medication trigger.1-3 Furthermore, it is found to coexist with other chronic dermatoses, such as atopic dermatitis, contact dermatitis, and xerosis.4 With an association and phenotypic overlap with atopic disease, we hypothesized that dupilumab (interleukin [IL]-4/13 blockade) might be clinically beneficial to patients with severe Grover disease.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words